Positive trial results have given GlaxoSmithKline’s HIV division hope that it could gain new ground in the market for HIV treatments.
A new injection developed by the company has proven to be just as effective as the standard course of medications. One of the major benefits is that the treatment would decrease the dosing by patients from three pills a day to two injections a month.
Reducing toxicity and the amount of daily medications needed to treat HIV have been common concerns among patients.
The company said that it intends to release more details about the study later this year and file for regulatory approval. The market for HIV treatments in the U.S. is currently dominated by Gilead Sciences.
Read the full Financial Times report.